![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Department of Internal Medicine II, Miyazaki Medical College, Miyazaki, Japan
Hepatocyte growth factor (HGF) modulates intestinal epithelial cell proliferation and migration, serving as a critical regulator of intestinal wound healing. In this study, we examined the effect of administration of recombinant human HGF on colonic mucosal damage in vivo. Acute colitis was induced in rats by feeding with 5% dextran sulfate sodium (DSS) for 7 days, and colitis was subsequently maintained by feeding with 1% DSS. On the 5th day of DSS administration, osmotic pumps releasing recombinant human HGF (200 µg/day) were implanted into the peritoneum of the rats. Continuous intraperitoneal delivery of HGF led to both increased serum human HGF levels and c-Met tyrosine phosphorylation within the colonic mucosa. Compared with mock-treated rats, those administered human HGF showed a reduction in colitis-associated weight loss, large intestinal shortening, and improved colonic erosions. Enhanced epithelial regeneration and cellular proliferation were observed in rats treated with recombinant human HGF. The weights of the liver, kidneys, and spleen were not affected by HGF administration. These results indicate that HGF administration accelerates colonic mucosal repair in rats with DSS-induced colitis and suggest that recombinant human HGF may be a useful therapeutic tool to facilitate intestinal wound healing in patients with ulcerative colitis.
Address correspondence to: Dr. Hirohito Tsubouchi, Department of Internal Medicine II, Miyazaki Medical College, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. E-mail: htsubo{at}post1.miyazaki-med.ac.jp
This article has been cited by other articles:
|
|
 |
|
  J. H. Chidlow Jr., D. Shukla, M. B. Grisham, and C. G. Kevil Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G5 - G18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kanayama, T. Takahara, Y. Yata, F. Xue, E. Shinno, K. Nonome, H. Kudo, K. Kawai, T. Kudo, Y. Tabuchi, et al. Hepatocyte growth factor promotes colonic epithelial regeneration via Akt signaling Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G230 - G239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Campbell, J. S. Sutcliffe, P. J. Ebert, R. Militerni, C. Bravaccio, S. Trillo, M. Elia, C. Schneider, R. Melmed, R. Sacco, et al. From the Cover: A genetic variant that disrupts MET transcription is associated with autism PNAS, November 7, 2006; 103(45): 16834 - 16839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yuki, S. Ishihara, M. A. K. Rumi, C. F. Ortega-Cava, Y. Kadowaki, H. Kazumori, N. Ishimura, Y. Amano, N. Moriyama, and Y. Kinoshita Increased expression of midkine in the rat colon during healing of experimental colitis. Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G735 - G743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oh, Y. Iimuro, M. Takeuchi, Y. Kaneda, T. Iwasaki, N. Terada, T. Matsumoto, K. Nakanishi, and J. Fujimoto Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G729 - G735. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
